BACKGROUND: Cognitive impairment secondary to frontal lobe atrophy exists in 40-60% of Amyotrophic Lateral Sclerosis (ALS) cases. We aimed to determine the prevalence of frontal-lobe mediated behavioral impairment in (ALS) and to ascertain its relationship to cognitive impairment. METHODS: Two-hundred and twenty five patients diagnosed with sporadic ALS were evaluated for behavioral dysfunction using the Frontal Systems Behavior Scale (FrSBe), a validated measure used to examine frontal-lobe mediated behaviors, specifically apathy, executive dysfunction and disinhibition; a total behavior score is also provided. Additionally, a subset of patients also underwent a comprehensive neuropsychological evaluation. RESULTS: Changes in the total FrSBe scores were observed in 24.4% of the patients and 39.6% of the patients had impairment in at least one behavioral domain with symptoms of Apathy being the most common (31.1%). Cognitively impaired ALS patients had worse total (P = 0.05) and apathy scores (P < 0.01); however, behavioral dysfunction was also present in 16% of the cognitively intact patients. Half of the behaviorally intact patients exhibited cognitive impairment. Significant correlations were observed for performance on certain neuropsychological tests (Animal fluency, Block Design, Logical Memory I and Verbal Series Attention Test) and severity of behavioral dysfunction on certain FrSBe sub scores. CONCLUSIONS: Frontal-lobe mediated behavioral dysfunction appears to be common in ALS. Cognitively impaired ALS patients had greater behavioral dysfunction. Recognition of behavioral and cognitive dysfunction may assist health-care providers and care-givers recognize changes in decision-making capacity and treatment compliance of patients with ALS.
BACKGROUND:Cognitive impairment secondary to frontal lobe atrophy exists in 40-60% of Amyotrophic Lateral Sclerosis (ALS) cases. We aimed to determine the prevalence of frontal-lobe mediated behavioral impairment in (ALS) and to ascertain its relationship to cognitive impairment. METHODS: Two-hundred and twenty five patients diagnosed with sporadic ALS were evaluated for behavioral dysfunction using the Frontal Systems Behavior Scale (FrSBe), a validated measure used to examine frontal-lobe mediated behaviors, specifically apathy, executive dysfunction and disinhibition; a total behavior score is also provided. Additionally, a subset of patients also underwent a comprehensive neuropsychological evaluation. RESULTS: Changes in the total FrSBe scores were observed in 24.4% of the patients and 39.6% of the patients had impairment in at least one behavioral domain with symptoms of Apathy being the most common (31.1%). Cognitively impaired ALSpatients had worse total (P = 0.05) and apathy scores (P < 0.01); however, behavioral dysfunction was also present in 16% of the cognitively intact patients. Half of the behaviorally intact patients exhibited cognitive impairment. Significant correlations were observed for performance on certain neuropsychological tests (Animal fluency, Block Design, Logical Memory I and Verbal Series Attention Test) and severity of behavioral dysfunction on certain FrSBe sub scores. CONCLUSIONS:Frontal-lobe mediated behavioral dysfunction appears to be common in ALS. Cognitively impaired ALSpatients had greater behavioral dysfunction. Recognition of behavioral and cognitive dysfunction may assist health-care providers and care-givers recognize changes in decision-making capacity and treatment compliance of patients with ALS.
Authors: Michael J Strong; Sharon Abrahams; Laura H Goldstein; Susan Woolley; Paula Mclaughlin; Julie Snowden; Eneida Mioshi; Angie Roberts-South; Michael Benatar; Tibor HortobáGyi; Jeffrey Rosenfeld; Vincenzo Silani; Paul G Ince; Martin R Turner Journal: Amyotroph Lateral Scler Frontotemporal Degener Date: 2017-01-05 Impact factor: 4.092
Authors: Jennifer Murphy; Pam Factor-Litvak; Raymond Goetz; Catherine Lomen-Hoerth; Peter L Nagy; Jonathan Hupf; Jessica Singleton; Susan Woolley; Howard Andrews; Daragh Heitzman; Richard S Bedlack; Jonathan S Katz; Richard J Barohn; Eric J Sorenson; Björn Oskarsson; J Americo M Fernandes Filho; Edward J Kasarskis; Tahseen Mozaffar; Yvonne D Rollins; Sharon P Nations; Andrea J Swenson; Boguslawa A Koczon-Jaremko; Hiroshi Mitsumoto Journal: Neurology Date: 2016-01-22 Impact factor: 9.910
Authors: Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan Journal: CNS Drugs Date: 2021-05-15 Impact factor: 5.749
Authors: Tamlyn J Watermeyer; Richard G Brown; Katie C L Sidle; David J Oliver; Christopher Allen; Joanna Karlsson; Catherine M Ellis; Christopher E Shaw; Ammar Al-Chalabi; Laura H Goldstein Journal: J Neurol Date: 2015-05-10 Impact factor: 4.849
Authors: Patricia Lillo; Eneida Mioshi; James R Burrell; Matthew C Kiernan; John R Hodges; Michael Hornberger Journal: PLoS One Date: 2012-08-29 Impact factor: 3.240